| CAS: | 1229236-86-5 | |
| 分子式: | C23H25ClFN7O | |
| 分子量: | 469.94 | |
| 中文名称: |
| |
| 英文名称: |
|
| 货号 | 品牌 | 产品名称 | 规格 | 包装、参考价格 | |||||||||||||||||||||||||||||
| L797094 | MACKLIN | Gandotinib | 10mM in DMSO | 926元/1ml; | 咨询 | ||||||||||||||||||||||||||||
储存：-20°C | |||||||||||||||||||||||||||||||||
| L833090 | MACKLIN | Gandotinib游离态 | 98% | 656元/5mg; 1109元/10mg; 3679元/50mg; | 咨询 | ||||||||||||||||||||||||||||
储存：-20°C 状态：白色到米黄色粉末 | |||||||||||||||||||||||||||||||||
| SML2567 | Sigma-Aldrich | LY2784544 | ≥98% (HPLC) | 1225.94元/5 MG; 4950.02元/25 MG; | 咨询 | ||||||||||||||||||||||||||||
产品说明 生化/生理作用 LY2784544 is an orally active, ATP-competitive, potent and JAK2-selective janus tyrosine kinase inhibitor (IC50/[ATP] = 2.52 nM/5 μM/JAK2, 19.8 nM/20 μM/JAK1, 48.0 nM/2 μM/JAK3) with little activity toward 79 other kinases. LY2784544 selectively inhibits signaling/proliferation driven by oncogenic JAK2V617F (IC50 = 20/55 nM) over those mediated by wt JAK2 upon IL-3 induction (IC50 = 1183/1309 nM) in Ba/F3 cultures and displays in vivo efficacious in a JAK2V617F-induced murine MPN model (10-80 mg/kg bid po.). LY2784544 is also reported to display Zn-dependent (optimal [Zn+2] = 100 μM) GPR39 agonist activity, but not 11 other GPRs. 基本信息
产品性质
安全信息
| |||||||||||||||||||||||||||||||||
m.cnreagent.com